Related Experiment Video
Updated: Jan 18, 2026
10:02
Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells
Published on: June 10, 2022
2.6K
Reversing PAI-1 deficiency in blood using mRNA lipid nanoparticles
Francesca Ferraresso1,2, Chad W Skaer1, Katherine Badior1
1Versiti Blood Research Institute, Milwaukee, WI 53226, USA.
Molecular Therapy. Methods & Clinical Development
|September 8, 2025
Summary
Messenger RNA (mRNA) therapy using lipid nanoparticles successfully increased plasminogen activator inhibitor-1 (PAI-1) levels in mice. This approach shows potential for treating bleeding and cardiac fibrosis in PAI-1 deficient patients.
Area of Science:
- Biochemistry
- Genetics
- Pharmacology
Background:
- Plasminogen activator inhibitor-1 (PAI-1) deficiency, caused by SERPINE-1 gene mutations, leads to bleeding and cardiac fibrosis.
- Current treatments for PAI-1 deficiency are limited due to the short half-life of replacement proteins.
Purpose of the Study:
- To develop and evaluate an mRNA-based therapy (mPAI-1) for endogenous PAI-1 production.
- To assess the efficacy of mPAI-1 in increasing circulating PAI-1 levels and inhibiting fibrinolysis.
Main Methods:
- Development of lipid nanoparticles encapsulating PAI-1 mRNA (mPAI-1).
- Intravenous administration of mPAI-1 in wild-type and PAI-1 knockout mice.
- Measurement of plasma PAI-1 levels, PAI-1 expression kinetics, and ex vivo fibrinolysis inhibition.
Main Results:
- mPAI-1 induced dose-dependent, supraphysiological PAI-1 expression in vivo.
- Circulating PAI-1 levels peaked at 6 hours post-injection and returned to baseline within 48 hours.
- Consistent PAI-1 production was observed after repeat dosing, and ex vivo fibrinolysis was inhibited.
Conclusions:
- mRNA therapy with mPAI-1 is a viable strategy to increase endogenous PAI-1 levels.
- This approach holds promise as a preventive therapy for bleeding and cardiac fibrosis in PAI-1 deficient individuals.
